SCHEMBL29784385

SCHEMBL29784385

O=C(O)c1ccc(-c2cccc(C(F)(F)F)c2)c(F)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 4/20 0.62
AKR1C2 P52895 4/20 0.62
SRD5A2 P31213 1/20 0.54
IP6K1 Q92551 1/20 0.53
IP6K3 Q96PC2 1/20 0.53
IP6K2 Q9UHH9 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
RXRA P19793 2/20 0.50
RXRB P28702 2/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
RXRG P48443 1/20 0.50
MGLL Q99685 1/20 0.49
KMO O15229 2/20 0.47
CNR2 P34972 1/20 0.47
CFTR P13569 1/20 0.46
CES2 O00748 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22442328 1.00 AKR1C3 (0.62) AKR1C3AKR1C2SRD5A2IP6K1IP6K3
SCHEMBL29771953 0.87 CNR2 (0.58) AKR1C3AKR1C2SRD5A2IP6K1IP6K3
SCHEMBL179120 0.84 SLC1A3 (0.54) AKR1C3AKR1C2SRD5A2IP6K1IP6K3
SCHEMBL505879 0.81 AKR1C3 (0.56) AKR1C3AKR1C2MEN1KMT2AKDM4E
SCHEMBL2744459 0.81 SLC1A3 (0.54) AKR1C3AKR1C2SRD5A2IP6K1IP6K3
SCHEMBL177461 0.81 RXRA (0.63) AKR1C3AKR1C2SRD5A2IP6K1IP6K3
SCHEMBL30393660 0.81 RXRA (0.63) AKR1C3AKR1C2SRD5A2IP6K1IP6K3
SCHEMBL2041007 0.81 RARB (0.56) AKR1C3AKR1C2MEN1KMT2AALDH1A1
SCHEMBL29473809 0.81 RARB (0.56) AKR1C3AKR1C2MEN1KMT2AALDH1A1
SCHEMBL22190055 0.81 IP6K1 (0.49) AKR1C3AKR1C2SRD5A2IP6K1IP6K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11390610-B2 Piperazine derivatives as MAGL inhibitors HOFFMANN-LA ROCHE INC. (US) 2022-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11390610-B2 Piperazine derivatives as MAGL inhibitors MAGI3, PYM1, MAG AKR1C3 2867/4885AKR1C2 3475/4885SRD5A2 4796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.